Cartee L, Kucera G L
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157-1082, USA.
Cancer Chemother Pharmacol. 1998;41(5):403-12. doi: 10.1007/s002800050758.
Cytosine arabinoside induces apoptosis and this cell death process is influenced by protein kinase C signaling events in leukemic cells. We present findings that extend these observations to include another deoxycytidine analog, gemcitabine, which is more potent in solid tumors.
Gemcitabine induced programmed cell death in BG-1 human ovarian cancer cells based on biochemical and morphologic analyses. The DNA was fragmented in BG-1 cells exposed to gemcitabine (0.5 microM, 1.0 microM and 10 microM) for 8 h, but gemcitabine treatment did not induce internucleosomal DNA degradation. Scanning and transmission electron microscopy of BG-1 cells showed morphologic changes associated with apoptosis in response to gemcitabine: membrane blebbing, the formation of apoptotic bodies and chromatin condensation. Thus, BG-1 cells undergo programmed cell death in response to gemcitabine treatment without internucleosomal DNA fragmentation. Furthermore, gemcitabine (10 microM) activated protein kinase C in BG-1 cells and the phosphorylation of the endogenous protein kinase C substrate, myristoylated alanine-rich C kinase substrate, was increased following exposure of BG-1 cells to gemcitabine for up to 6 h. Clonogenicity studies with gemcitabine in combination with various protein kinase C-modulating agents demonstrated that gemcitabine cytotoxicity was influenced by protein kinase C signaling events in BG-1 cells. Short-term (1 h) exposure to TPA (1 or 10 nM) followed by gemcitabine (0.5 microM for 4 h) did not alter the response to gemcitabine. However, a 24-h exposure to TPA followed by gemcitabine resulted in synergistic cytotoxicity, while coincubation of TPA with a PKC inhibitor (e.g. bisindolylmaleimide or calphostin-C) in this regimen abrogated the synergistic response.
Based on our findings, it is plausible that gemcitabine therapy could be improved by modulating PKC signaling events linked to drug-induced apoptosis/cytotoxicity.
阿糖胞苷可诱导细胞凋亡,且白血病细胞中的蛋白激酶C信号转导事件会影响这一细胞死亡过程。我们的研究结果将这些观察结果扩展至另一种脱氧胞苷类似物吉西他滨,其在实体瘤中更具效力。
基于生化和形态学分析,吉西他滨可诱导BG-1人卵巢癌细胞发生程序性细胞死亡。暴露于吉西他滨(0.5微摩尔/升、1.0微摩尔/升和10微摩尔/升)8小时的BG-1细胞中的DNA发生片段化,但吉西他滨处理并未诱导核小体间DNA降解。BG-1细胞的扫描电镜和透射电镜显示,对吉西他滨的反应出现了与凋亡相关的形态学变化:细胞膜起泡、凋亡小体形成和染色质浓缩。因此,BG-1细胞在吉西他滨处理后会经历程序性细胞死亡,而无核小体间DNA片段化。此外,吉西他滨(10微摩尔/升)可激活BG-1细胞中的蛋白激酶C,在BG-1细胞暴露于吉西他滨长达6小时后,内源性蛋白激酶C底物(富含肉豆蔻酰化丙氨酸的C激酶底物)的磷酸化增加。吉西他滨与各种蛋白激酶C调节剂联合进行的克隆形成研究表明,吉西他滨的细胞毒性受BG-1细胞中蛋白激酶C信号转导事件的影响。短期(1小时)暴露于佛波酯(1或10纳摩尔/升)后再给予吉西他滨(0.5微摩尔/升,持续4小时),并未改变对吉西他滨的反应。然而,24小时暴露于佛波酯后再给予吉西他滨会导致协同细胞毒性,而在此方案中,将佛波酯与蛋白激酶C抑制剂(如双吲哚马来酰胺或钙泊三醇)共同孵育可消除这种协同反应。
基于我们的研究结果,通过调节与药物诱导的凋亡/细胞毒性相关的蛋白激酶C信号转导事件来改善吉西他滨治疗似乎是可行的。